865305-30-2

Basic information

• Product Name: 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]-
• Synonyms: 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]-;AF 353;Ro 4;5-{[5-iodo-2-(1-Methylethyl)-4-(Methyloxy)phenyl]oxy}-2,4-pyriMidinediaMine;5-[5-Iodo-4-methoxy-2-(1-methylethyl)phenoxy]-2,4-pyrimidinediamine;AF-353 (Ro-4)
• CAS NO: 865305-30-2
• Molecular Formula: C₁₄H₁₇IN₄O₂
• Molecular Weight: 400.21485
• Product Categories: Inhibitors
• Mol File: 865305-30-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 510.2±60.0 °C(Predicted)
• Appearance: /
• Density: 1.619±0.06 g/cm3(Predicted)
• PKA: 6.89±0.10(Predicted)
• CAS DataBase Reference: 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]-(865305-30-2)
• EPA Substance Registry System: 2,4-PyriMidinediaMine, 5-[5-iodo-4-Methoxy-2-(1-Methylethyl)phenoxy]-(865305-30-2)

Safety Data

• Hazardous Substances Data: 865305-30-2(Hazardous Substances Data)

Usage

Description

AF-353 is a noncompetitive dual antagonist of the purinoreceptors P2X3 and P2X2/3 (IC50s = 10 and 79.4 nM, respectively). It is selective for P2X3 and P2X2/3 over P2X1, P2X2, P2X4, P2X5, and P2X7 (IC50 = >10 μM for all). It inhibits calcium flux in CHO-K1 cells expressing the rat P2X3 receptor and in 1321N1 cells expressing the human P2X3 and P2X2/3 receptors (IC50s = 8.91, 8.71, and 38.9 nM, respectively). AF-353 decreases the electrical signals in the detrusor, but not striated, muscle of the bladder in female rats.

Upstream product

• 1145716-81-9 C₁₄H₁₆INO₃ 
• 593-85-1 diguanidine carbonate 
• 865304-71-8 5-(2-isopropyl-4-methoxy-phenoxy)-pyrimidine-2,4-diamine 

Downstream Products

• 865305-31-3 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzonitrile 
• 865305-75-5 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-thiobenzamide 
• 927875-14-7 N-[4-amino-5-(5-iodo-2-isopropyl-4-methoxy-phenoxy)-pyrimidin-2-yl]-acetamide 
• 1050371-24-8 N-[4-amino-5-(5-iodo-2-isopropyl-4-methoxy-phenoxy)-pyrimidin-2-yl]-2-chloro-acetamide 
• 1161408-63-4 2-(Boc-amino)-N-[4-amino-5-(5-iodo-2-isopropyl-4-methoxy-phenoxy)-pyrimidin-2-yl]-3-methyl-butyramide 

Relevant articles and documents

METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS

Provided herein include methods and compositions for treating diseases or conditions. In some embodiments provided are methods for treating one or more diseases or conditions selected from the group consisting of hypertension, heart failure, dyspnea, and

Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain

P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X3 and P2X2/3 receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X3/P2X2/3 antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X3/P2X2/3 antagonist.

Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.